vs
Side-by-side financial comparison of Gilead Sciences (GILD) and Smurfit Westrock (SW). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $7.7B, roughly 1.0× Smurfit Westrock). Gilead Sciences runs the higher net margin — 27.5% vs 0.8%, a 26.7% gap on every dollar of revenue. On growth, Gilead Sciences posted the faster year-over-year revenue change (4.7% vs 0.7%). Over the past eight quarters, Smurfit Westrock's revenue compounded faster (61.2% CAGR vs 8.9%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Smurfit Westrock plc is an Irish company based in Dublin, Ireland that manufactures corrugated and paper-based packaging. Its stock is listed on the New York Stock Exchange and the London Stock Exchange.
GILD vs SW — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $7.7B |
| Net Profit | $2.2B | $63.0M |
| Gross Margin | 79.5% | 16.4% |
| Operating Margin | 25.0% | 3.3% |
| Net Margin | 27.5% | 0.8% |
| Revenue YoY | 4.7% | 0.7% |
| Net Profit YoY | 22.4% | 0.0% |
| EPS (diluted) | $1.75 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $7.7B | ||
| Q4 25 | $7.9B | $7.6B | ||
| Q3 25 | $7.8B | $8.0B | ||
| Q2 25 | $7.1B | $7.9B | ||
| Q1 25 | $6.7B | $7.7B | ||
| Q4 24 | $7.6B | $7.5B | ||
| Q3 24 | $7.5B | $7.7B | ||
| Q2 24 | $7.0B | $3.0B |
| Q1 26 | — | $63.0M | ||
| Q4 25 | $2.2B | $97.0M | ||
| Q3 25 | $3.1B | $246.0M | ||
| Q2 25 | $2.0B | $-28.0M | ||
| Q1 25 | $1.3B | $384.0M | ||
| Q4 24 | $1.8B | $146.0M | ||
| Q3 24 | $1.3B | $-150.0M | ||
| Q2 24 | $1.6B | $132.0M |
| Q1 26 | — | 16.4% | ||
| Q4 25 | 79.5% | 18.2% | ||
| Q3 25 | 79.8% | 19.6% | ||
| Q2 25 | 78.8% | 19.1% | ||
| Q1 25 | 76.9% | 20.6% | ||
| Q4 24 | 79.1% | 19.1% | ||
| Q3 24 | 79.1% | 17.6% | ||
| Q2 24 | 77.8% | 23.3% |
| Q1 26 | — | 3.3% | ||
| Q4 25 | 25.0% | 5.1% | ||
| Q3 25 | 42.8% | 6.6% | ||
| Q2 25 | 34.9% | 3.2% | ||
| Q1 25 | 33.6% | 7.2% | ||
| Q4 24 | 32.4% | 5.3% | ||
| Q3 24 | 11.8% | 0.7% | ||
| Q2 24 | 38.0% | 8.2% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 27.5% | 1.3% | ||
| Q3 25 | 39.3% | 3.1% | ||
| Q2 25 | 27.7% | -0.4% | ||
| Q1 25 | 19.7% | 5.0% | ||
| Q4 24 | 23.6% | 1.9% | ||
| Q3 24 | 16.6% | -2.0% | ||
| Q2 24 | 23.2% | 4.4% |
| Q1 26 | — | $0.12 | ||
| Q4 25 | $1.75 | $0.18 | ||
| Q3 25 | $2.43 | $0.47 | ||
| Q2 25 | $1.56 | $-0.05 | ||
| Q1 25 | $1.04 | $0.73 | ||
| Q4 24 | $1.43 | $-0.12 | ||
| Q3 24 | $1.00 | $-0.30 | ||
| Q2 24 | $1.29 | $0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | — |
| Total DebtLower is stronger | $24.9B | $980.0M |
| Stockholders' EquityBook value | $22.7B | $18.1B |
| Total Assets | $59.0B | $45.2B |
| Debt / EquityLower = less leverage | 1.10× | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $68.0M | $892.0M | ||
| Q3 25 | $19.0M | $851.0M | ||
| Q2 25 | $69.0M | $778.0M | ||
| Q1 25 | — | $797.0M | ||
| Q4 24 | — | $855.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $26.8K |
| Q1 26 | — | $980.0M | ||
| Q4 25 | $24.9B | $13.4B | ||
| Q3 25 | $24.9B | $13.3B | ||
| Q2 25 | $24.9B | $13.3B | ||
| Q1 25 | $25.0B | $12.9B | ||
| Q4 24 | $26.7B | $12.5B | ||
| Q3 24 | $23.2B | $13.2B | ||
| Q2 24 | $23.3B | — |
| Q1 26 | — | $18.1B | ||
| Q4 25 | $22.7B | $18.3B | ||
| Q3 25 | $21.5B | $18.4B | ||
| Q2 25 | $19.7B | $18.3B | ||
| Q1 25 | $19.2B | $17.9B | ||
| Q4 24 | $19.3B | $17.4B | ||
| Q3 24 | $18.5B | $18.0B | ||
| Q2 24 | $18.3B | $14.5K |
| Q1 26 | — | $45.2B | ||
| Q4 25 | $59.0B | $45.2B | ||
| Q3 25 | $58.5B | $45.6B | ||
| Q2 25 | $55.7B | $45.7B | ||
| Q1 25 | $56.4B | $44.6B | ||
| Q4 24 | $59.0B | $43.8B | ||
| Q3 24 | $54.5B | $45.0B | ||
| Q2 24 | $53.6B | $26.8K |
| Q1 26 | — | 0.05× | ||
| Q4 25 | 1.10× | 0.73× | ||
| Q3 25 | 1.16× | 0.72× | ||
| Q2 25 | 1.27× | 0.73× | ||
| Q1 25 | 1.30× | 0.72× | ||
| Q4 24 | 1.38× | 0.72× | ||
| Q3 24 | 1.26× | 0.73× | ||
| Q2 24 | 1.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $204.0M |
| Free Cash FlowOCF − Capex | $3.1B | — |
| FCF MarginFCF / Revenue | 39.4% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 1.52× | 3.24× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $204.0M | ||
| Q4 25 | $3.3B | $1.2B | ||
| Q3 25 | $4.1B | $1.1B | ||
| Q2 25 | $827.0M | $829.0M | ||
| Q1 25 | $1.8B | $235.0M | ||
| Q4 24 | $3.0B | $781.0M | ||
| Q3 24 | $4.3B | $320.0M | ||
| Q2 24 | $1.3B | $340.0M |
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $612.0M | ||
| Q3 25 | $4.0B | $523.0M | ||
| Q2 25 | $720.0M | $307.0M | ||
| Q1 25 | $1.7B | $-242.0M | ||
| Q4 24 | $2.8B | $212.0M | ||
| Q3 24 | $4.2B | $-192.0M | ||
| Q2 24 | $1.2B | $163.0M |
| Q1 26 | — | — | ||
| Q4 25 | 39.4% | 8.1% | ||
| Q3 25 | 51.0% | 6.5% | ||
| Q2 25 | 10.2% | 3.9% | ||
| Q1 25 | 24.8% | -3.2% | ||
| Q4 24 | 37.4% | 2.8% | ||
| Q3 24 | 55.2% | -2.5% | ||
| Q2 24 | 17.2% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 7.7% | ||
| Q3 25 | 1.9% | 7.6% | ||
| Q2 25 | 1.5% | 6.6% | ||
| Q1 25 | 1.6% | 6.2% | ||
| Q4 24 | 1.9% | 7.5% | ||
| Q3 24 | 1.9% | 6.7% | ||
| Q2 24 | 1.9% | 6.0% |
| Q1 26 | — | 3.24× | ||
| Q4 25 | 1.52× | 12.32× | ||
| Q3 25 | 1.35× | 4.61× | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 1.34× | 0.61× | ||
| Q4 24 | 1.67× | 5.35× | ||
| Q3 24 | 3.44× | — | ||
| Q2 24 | 0.82× | 2.58× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
SW
Segment breakdown not available.
